20.12.2021 22:31:02
|
New Zealand Authorities Link 26-year-old Man's Death To Pfizer's Covid Vaccine
(RTTNews) - New Zealand authorities on Monday said they had linked a 26-year-old man's death to Pfizer's (PFE) Covid-19 vaccine after the man died probably due to myocarditis after taking his first dose.
This is the second death in New Zealand that has been linked to a known but rare side effect from the vaccine. In August, a woman had died after taking the vaccine.
"With the current available information, the board has considered that the myocarditis was probably due to vaccination in this individual," a Covid-19 Vaccine Independent Safety Monitoring Board said in a statement.
"There were no reported symptoms prior to the vaccine and the symptoms of myocarditis developed in the days immediately following his first vaccine dose," the statement added.
The man also did not seek any medical advice or treatment for his symptoms. Myocarditis is an inflammation of the heart muscle that can limit the organ's ability to pump blood and can cause changes in heartbeat rhythms. Myocarditis is a treatable condition, if identified, and outcomes are better the earlier that treatment is started.
Moving ahead, the New Zealand authorities said that "the circumstances of these cases do not impact or change the known information on myocarditis, and the benefits of vaccination with the Pfizer vaccine for COVID-19 continue to greatly outweigh the risk of such rare side effects."

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
18.02.25 |
S&P 500-Wert Pfizer-Aktie: So viel Verlust hätte ein Pfizer-Investment von vor einem Jahr eingefahren (finanzen.at) | |
11.02.25 |
S&P 500-Titel Pfizer-Aktie: So viel hätten Anleger mit einem Investment in Pfizer von vor 10 Jahren verloren (finanzen.at) | |
04.02.25 |
Pfizer CEO ‘disappointed’ by Kennedy’s refusal to rebut claims on jab risks (Financial Times) | |
04.02.25 |
AKTIEN IM FOKUS: Ausblick bringt Merck & Co unter Druck - Pfizer auch im Minus (dpa-AFX) | |
04.02.25 |
ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 30 Dollar (dpa-AFX) | |
04.02.25 |
Pfizer vermeldet Umsatzsprung - Aktie dennoch schwächer (dpa-AFX) | |
04.02.25 |
S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte ein Pfizer-Investment von vor 5 Jahren eingebracht (finanzen.at) | |
04.02.25 |
Ausblick: Pfizer stellt Zahlen zum jüngsten Quartal vor (finanzen.net) |
Analysen zu Pfizer Inc.mehr Analysen
05.02.25 | Pfizer Kaufen | DZ BANK | |
05.02.25 | Pfizer Buy | Goldman Sachs Group Inc. | |
05.02.25 | Pfizer Neutral | UBS AG | |
05.02.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
04.02.25 | Pfizer Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Pfizer Inc. | 25,17 | 2,19% |
|